Novel targeted therapies and immunotherapy for advanced thyroid cancers

Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most anaplastic types, remain resistant to standard treatment options, including radioactive iodine (RAI). In addition, around 30%...

Descripción completa

Detalles Bibliográficos
Autores principales: Naoum, George E., Morkos, Michael, Kim, Brian, Arafat, Waleed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817719/
https://www.ncbi.nlm.nih.gov/pubmed/29455653
http://dx.doi.org/10.1186/s12943-018-0786-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817719/
https://www.ncbi.nlm.nih.gov/pubmed/29455653
http://dx.doi.org/10.1186/s12943-018-0786-0

Ejemplares similares